The multidisciplinary USC cardiopulmonary transplant team is composed of experts in their respective fields of cardiothoracic surgery, cardiology, pulmonary medicine, immunology, critical care medicine, cystic fibrosis, immunosuppression, and rehabilitation. The team consists of world-recognized leaders and innovators in heart, heart-lung, lung transplantation and cardiothoracic surgery. Anthem has designated our program as a Center of Medical Excellence, and Keck Hospital of USC is certified for Medicare for lung transplantation.
Pulmonary (lung) transplantation has become a viable treatment option for patients with end-stage cardiopulmonary disease. Patients eligible for pulmonary transplantation include any person who is severely debilitated by cardiopulmonary disease and is not hampered by any other organ system dysfunction. Candidates frequently have the diagnosis of obstructive lung disease, such as:
- Cystic fibrosis
- Pulmonary hypertension (both primary and secondary)
- Pulmonary fibrosis (e.g. sarcoidosis, IPF, silicosis)
Restrictions to transplantation include:
- Severe obesity
- Active neoplastic disease
- Systemic or untreatable local infection
- Tobacco or drug dependency
- Lack of adequate support systems
- Inability to comply with a strict medical regimen
- Patients on chronic mechanical ventilation will be considered on a case-by-case basis.
Living-related lobar transplantation was pioneered by Vaughn Starnes, MD, at Keck Medicine of USC in Los Angeles and provides an alternative therapy for severely ill patients who are unlikely to survive the waiting that is often required for deceased-donated organs to be available. Strict criteria must be met before a patient can qualify for these living-related procedures.
Our comprehensive program includes constant transplant team communication with patient/family regarding all aspects of patients’ medical care.
USC’s lung transplantation program is part of Aetna’s Institutes of Excellence™ Network.